FDA clears Viatronix 3D cardiac application

Viatronix, a developer of 3D imaging software, has received FDA’s 510(k) market clearance for its V3D-Cardiac module.

The V3D-Cardiac application combines left ventricle and coronary analysis functions into a single user-friendly module, allowing both functions are analyzed in a single application according to the Stony Brook, N.Y.-based company.

Viatronix said that the V3D-Cardiac module has real-time analysis of cardiac CTC data; integration with PACS workstations; one-click segmentation of the heart; one-click selection and analysis of coronary vessels; multi-phase cardiac function review; computation of ejection fraction; coronary vessel endoluminal fly-through; one-click segmentation of the left ventricle and automatic determination of long axis; and customizable reporting is integrated into the workflow.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.